HOME >> MEDICINE >> NEWS
Treatment has demonstrated improvement in physical function and kept joint damage from progressing

THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa., November 13, 2005 Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced data from a long-term blinded study of anti-TNF agent in patients with rheumatoid arthritis (RA) demonstrated that more than three quarters of patients treated with Enbrel (etanercept) plus methotrexate combination therapy experienced no progression of joint damage at three years. These new results from the TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study will be presented at the American College of Rheumatology's (ACR) Annual Scientific Meeting in San Diego, California.

"Rheumatoid arthritis is a chronic condition requiring long-term treatment. It is critical to provide patients with treatment options that not only reduce the signs and symptoms of the disease, but also inhibit the progression of joint damage," said Dsire van der Heijde, M.D., professor of rheumatology, University of Maastricht in the Netherlands. "The TEMPO results reinforce the benefits of ENBREL and methotrexate combination therapy and underscore the importance of effective treatment."

At three years, the majority of patients taking ENBREL and methotrexate combination therapy had no progression of joint damage. These results were significantly better than those achieved in ENBREL monotherapy and methotrexate monotherapy-treated patients. Patients receiving ENBREL monotherapy also had significantly better results than patients receiving methotrexate monotherapy. Total Sharp Score was calculated by assessing changes in joint space narrowing and bone erosion as captured by radiographic imaging.

Further, additional data presented at ACR showed that improvement in physical function was higher for the ENBREL combination group than for either therapy alone. Patients treated with ENBREL combination therapy experienced a 56 percent mean improvement in Health Assessment
'"/>

Contact: Christine Cassiano, Amgen
805-447-4587
Porter Novelli
15-Nov-2005


Page: 1 2

Related medicine news :

1. Treatment for early prostate cancer associated with type of specialist seen
2. Treatment outcomes of patients with HIV and tuberculosis
3. Treatment of kidney condition requires an individualized approach
4. Treatment of in-hospital cardiac patients is focus of Jefferson University presentations
5. Treatment for homeless youth pays off in long run, study finds
6. Treatment discovered for deadly childhood disease
7. Treatment developed for patients with medically unexplained symptoms
8. Treatment drug may cause jawbone to die
9. Treatment for anorexia nervosa appears to have improved outcome
10. Treatment reduces gastric ulcers in at-risk patients using long-term NSAIDS
11. North Central Cancer Treatment Group finding ways to make treatment easier

Post Your Comments:
(Date:10/30/2014)... 2014 Timothy, InstaKNOT’s 4-year-old ... firefighters, showing that you are never too young to ... firefighters Tracey and Carl at the 2013 Santa Arriving ... Pompano Beach Chamber of Commerce. Tracey gave Timothy a ... Timothy wear his real fireman’s hat, and extending an ...
(Date:10/30/2014)... 2014 Don Allred Insurance, a leading ... plans for North Carolina residents, is excited to announce ... Holly Hill Mall. The new branch has been up ... customers through all facets of the insurance selection process ... spokesman Scott Allred couldn’t be happier with the timing ...
(Date:10/30/2014)... Portland, OR (PRWEB) October 30, 2014 ... law firm Hodgkinson Street LLC announces new branding ... Hodgkinson Street Mepham . After David Mepham’s promotion ... revitalizes their brand and website to include Mepham’s name ... leading medical malpractice and mediation firm, the decision to ...
(Date:10/30/2014)... 2014 Paramount Rx, a full-service prescription ... efforts to help people save money through its innovative ... for prescription drugs in the new health care system, ... to bridge the relationship between consumers, businesses and the ... challenges people face today with medical costs is the ...
(Date:10/30/2014)... HealthDay Reporter , WEDNESDAY, Oct. ... with prostate cancer who also have certain heart problems may ... new study suggests. , , The therapy in question is called ... reduce levels of male hormones to prevent the growth of ... research, this hormone therapy was linked to triple the risk ...
Breaking Medicine News(10 mins):Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 2Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 3Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 4Health News:Allred Insurance Satellite Office Grand Opening 2Health News:Hodgkinson Street Mepham Rebrands 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 3Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 3
(Date:10/30/2014)... FRANCISCO , Oct. 30, 2014  Nektar Therapeutics ... results for the third quarter ended September 30, 2014 ... U.S.-based financial markets. Howard Robin , president and ... review the results beginning at 5:00 p.m. Eastern Time ... press release and a live audio-only Webcast of the ...
(Date:10/30/2014)... , Oct. 30, 2014  CytRx Corporation ... and development company specializing in oncology, today announced ... its lead drug candidate, aldoxorubicin.  The presentation, titled, ... Approach," will be given by Sant P. ... Oncology Center and principal investigator of the Company,s ...
(Date:10/30/2014)... -- , Extensively hydrolyzed milk formula with LGG ... Cow milk protein allergy (CMPA) is the leading cause of food ... has been managed by eliminating milk proteins from a ... is possible to help build of oral tolerance to ... the first year of life by using an extensively ...
Breaking Medicine Technology:Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 4Experts Present Latest Research at Allergy Day 2Experts Present Latest Research at Allergy Day 3
Cached News: